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a  b  s  t  r  a  c  t
Arboviruses pose a serious threat to public health worldwide, overloading the healthcare
system and causing economic losses. These viruses form a very diverse group, and in Brazil,
arboviruses belonging to the families Flaviviridae and Togaviridae are predominant. Unfortu-
nately, the number of arboviruses increases in proportion with factors such as deforestation,
poor  sanitation, climate changes, and introduction of new viruses like Chikungunya virus
and  Zika virus.
In Brazil, dengue is endemic, along with the presence of other arboviruses. The situation
is  complicated by the scarcity of diagnostic infrastructure and the absence of approved
vaccines for these diseases. Disease control, thus, relies solely on vector control. Therefore,
enhanced clinical knowledge and improved general awareness about these arboviruses are
indispensable to tackle diagnostic inadequacies.
Mayaro
Zika
© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
(MAYV). This situation, coupled with the introduction of
Chikungunya virus (CHIKV), followed by Zika virus (ZIKV), inIntroduction
Arboviruses (arthropod-borne viruses) pose a serious threat
to public health worldwide, especially in the tropical and sub-
tropical countries, overloading the public healthcare system
and causing economic losses. Despite these huge risks, the
number of cases tends to increase because of diverse concomi-
tant factors. Deforestation, migration, disordered occupation
of urban areas, and poor sanitation as well as ongoing climate
changes, which further aids the vectors of these diseases to
∗ Corresponding author.
E-mail: mnogueira@famerp.br (M.L. Nogueira).
http://dx.doi.org/10.1016/j.bjm.2016.10.008
1517-8382/© 2016 Sociedade Brasileira de Microbiologia. Published by 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)colonize new areas, will signiﬁcantly increase the strength of
population at risk.
These arboviruses form a very diverse group. In Brazil,
the main arbovirus causing epidemics belongs to the fami-
lies Flaviviridae and Togaviridae.1 In addition to the endemic
arboviruses such as dengue virus (DENV), other neglected
arboviruses also cause epidemics, such as Mayaro virusthe Brazilian territory highlights the importance of continuous
survey and research about these viruses. Improved awareness
Elsevier Editora Ltda. This is an open access article under the CC
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bout these viruses among physicians, healthcare personnel,
nd concerned authorities as well as general public in the
ffected areas is indispensable for disease control. This review
ill focus on the endemic DENV, the neglected MAYV,  and the
ewcomers CHIKV and ZIKV.
engue  fever
ackground
ENV are the most important human arboviruses found
orldwide, transmitted by mosquitoes of the genus Aedes,
he main vector being Aedes aegypti, and are responsible for
orbidity and mortality. This group is the etiological agent of
engue fever (DF). DENV activity in Brazil, during its trajec-
ory, is demonstrated by the high number of cases reported
s well as the number of states involved in the epidemics.
e. aegypti is observed in ∼80% of the country, and the dif-
culties of implementing successful vector control are well
nown. Explosive epidemics have become a socially and polit-
cally signiﬁcant public health problem, with great economic
mpact.2
The DENV species includes four genetically and antigeni-
ally different serotypes (DENV-1, -2, -3, and -4). DENV are
embers of the family Flaviviridae, genus Flavivirus.  Like other
aviviruses, DENV have a single-stranded positive-sense RNA
enome, 10,700-nucleotide-long, that is translated as a single
olyprotein and post-translationally cleaved into three struc-
ural proteins: capsid, premembrane and envelope; and seven
onstructural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B,
nd NS5.3
DENV-1 was the most predominant serotype in Brazil in
he 1980s, and DENV-2 replaced it in the 1990s; subsequently,
ENV-3 took the position in 2000, followed by DENV-4 in
007.4,5
ENV-1
ENV-1 was ﬁrst observed in the eighties. Phylogenetic studies
lassiﬁed DENV-1 into ﬁve genotypes, namely, I, II, III, IV, and
, on the basis of their genetic diversity.6 The genotypes I, IV,
nd V were observed in the country, unlike II and III.7,8
Nucleotide sequencing subdivided the genotype V into
hree lineages.9 The authors suggested that it was introduced
y four different events: the ﬁrst in 1984–1985, second in
997–1999, and third and fourth in 2004–2007. Two distinct lin-
ages were reported for viruses belonging to genotype V10;
hese lineages were introduced at different time-points in
oiás state. Genotype V was reported in Manaus11 and Minas
erais12 states.
ENV-2
o-circulation of DENV-1 and DENV-2 in Brazil began in
990, initially in Rio de Janeiro, and subsequently in other
tates.13–16 Similar to other countries in the Americas,
he introduction of this strain coincided with that of the
outheast Asian genotype DENV-2 into the continent. Two i o l o g y 4 7 S (2 0 1 6) 38–50 39
additional DENV-2 epidemics occurred in 1998 and 2007–2008
in Brazil. In 2001, a large outbreak of DENV-2 occurred in
Manaus.17
Two lineages of DENV-2 have been reported in Brazil.18
Phylogenetic analyses of DENV-2 showed that genotype III
(Southeast Asian/American) was the only one that circulated
over the past 19 years in Brazil, from 1991 to 2008.19 Sequenc-
ing of samples collected in 2011 showed the presence of
DENV-2 of the Asian/American genotype in Manaus.11 Sal-
vador et al. later isolated an American genotype strain in
Brazil.20
DENV-3
Phylogenetic studies have classiﬁed DENV-3 into ﬁve geno-
types, namely, I, II, III, IV, and V, on the basis of their
genetic diversity.21 In Brazil, DENV-3 was ﬁrst isolated from
an autochthonous case in December 2000, in the state of
Rio de Janeiro. A large DENV epidemic occurred in 2001–2002
and DENV-3 was assigned to genotype III.22,23 These DENV-
3 isolates appeared to arise from single introduction of
GIII.24
Co-circulation of DENV-3 genotypes I and III was later
observed in Minas Gerais, Brazil. The genotype I was iden-
tiﬁed in outbreaks occurring during 2002–2004.25,26 Analysis
of the gene sequences of mosquitoes naturally infected with
DENV-3 conﬁrmed the circulation of genotype I in Minas
Gerais.27
DENV-3 genotype III is prevalent in Brazil and has also been
observed in Manaus, Amazonas state11 and in São José do Rio
Preto, São Paulo State.28 Phylogenetic analysis of the DENV-
3 genotype III isolated from 107 samples collected between
2001 and 2009 showed that four instances of genotype intro-
duction might have occurred in Brazil because of the detection
of four phylogenetically distinct lineages. Three lineages were
probably imported from the Antilles and Caribbean, while
the fourth one was probably introduced through Colombia or
Venezuela.29
A gap of eight years between two instances of introduction
has been suggested.30 Both lineages seem to be co-circulating
simultaneously, although lineage II is predominant in South
and Northeast Brazil, indicating that periodic DENV serotype-
speciﬁc peaks in incidence coincide with the introduction of
new lineages in Brazil every 7–10 years.
DENV-4
DENV-4 was ﬁrst reported in Roraima State during 1981 and
1982.31 DENV-4 reemerged in Manaus, Amazonas State in
2007.25 The virus was subsequently identiﬁed in the north-
ern Brazilian states of Amazonas and Pará.32 In the Southeast
region, the ﬁrst episode occurred in the states of Rio de Janeiro
and São Paulo in 2011.33,34
Partial genomic studies have conﬁrmed that the predom-
inant virus in Brazil is directly associated to the Caribbean
strains, and belongs to genotype II. Phylogenetic analyses of
different strains demonstrated the presence of two  distinct
genotypes I and II in Brazil.11,32,34–40
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Co-infections
In Brazil, clinical cases of co-infection with two serotypes
have been reported in some outbreaks. Co-infection with the
serotypes DENV-1/-4 and DENV-2/-4 were observed in Mato
Grosso state41; co-infection with DENV-1/-4, in São José do
Rio Preto, São Paulo state42; co-infection with DENV-1/-4,
DENV-2/-4, DENV-1/-2, and DENV-3/-4, in Manaus, Ama-
zonas state11,43,44; co-infection with DENV-2/-3, in Tauá, Ceará
state45; co-infection with DENV-1/-2, in Barretos, São Paulo
state46; and co-infection with DENV-1/-2, in Cuiabá, Mato
Grosso state.47,48 Co-infections with more  than one serotype
were also detected in Ae. aegypti.
Clinical  manifestations
In 1780, an epidemic of “breakbone fever” was reported in
Philadelphia, in which patients showed some or all of the fol-
lowing symptoms: high fever, headache, myalgia, arthralgia,
nausea, vomiting, rash, and hemorrhagic manifestations.49 In
1801, a similar syndrome was given the name of “dengue”
(meaning “affectation” in Spanish) to describe the plaintive
demeanor of patients.50 Dengue hemorrhagic fever, a severe
illness form, emerged a little more  than 60 years ago, when
21 cases of a severe febrile illness in children living in or near
Manila were identiﬁed.51
All four DENV serotypes cause similar forms of illness.52
DF is a complex illness, with a wide spectrum of clinical man-
ifestations, which, often, are unrecognized or misdiagnosed
as other fever-causing tropical illness. Among symptomatic
cases of DF, a wide variety of clinical manifestations can be
observed, ranging from mild febrile illness to severe DF and
potentially fatal DHF.53 After an incubation period of 3–5 days
(usually 5–8), the illness begins abruptly and passes through
three phases: febrile, critical, and recovery. DF (non-severe)
is characterized by a combination of two or more  signs and
symptoms in a febrile individual in an endemic area, includ-
ing nausea, vomiting, rash, aches, and pains, with a positive
tourniquet test, according to the latest World Health Organiza-
tion classiﬁcation.54 These symptoms occur during the early
febrile stage.55 In the critical phase, rashes are observed along
with the appearance of petechial exanthem, which occurs
around the time of defervescence, typically on days 3–7,
and is associated with capillary leakage and hemorrhage.56
Abdominal pain and tenderness, persistent vomiting, clinical
ﬂuid accumulation, mucosal bleeding, lethargy, restlessness,
and hepatomegaly are warning signs in potentially severe
cases of DF. The severe cases are characterized by capillary
leakage, which can lead to shock or ﬂuid accumulation,
causing respiratory distress, severe bleeding, and organ
failure, including the liver, central nervous system, and heart.
Thrombocytopenia (<100,000 mm3), not necessarily restricted
to the severe form, and “hemoconcentration” (increase in
hematocrit) may occur, which may be associated to plasma
leakage.52 Only a small proportion of patients progresses to
more  severe form.57 Although severe illness is historically
associated with pediatric populations in the hyper-endemic
regions,58,59 current trends show that adults may also be
at risk.60–63 The risk factors for the development of severe
DF include prior infection by the heterotypic serotype,64 b i o l o g y 4 7 S (2 0 1 6) 38–50
but, currently, the ability to predict the development of
complications such as shock due to systemic vascular leak
syndrome is currently poor.53 Although the clinical deﬁnition
of DF is available, clinical and laboratory presentations do
vary in some cases, often overlapping with other infections;
therefore, laboratory conﬁrmation is considered plausible.
The dynamic nature of DF demands close monitoring and
repeated clinical and laboratory evaluation, including peri-
odic check of hematocrit and platelet counts.65 The primary
concern for clinicians treating such patients remains the fact
that clinical diagnosis of DF is difﬁcult during the early febrile
phase. Careful clinical observation and judicious use of intra-
venous ﬂuid therapy are crucial. No DF-speciﬁc drugs are
available for therapy.
While the acute manifestations of DF are well known,
only few studies have reported clinical manifestations during
convalescence. The long-term consequences of the cross-
reactivity of antibodies against DENV and the associated
effects in plasmin activity,66 which, in turn, increases the
long-term risk of hemorrhagic phenomena in DENV-infected
patients, too remain unknown. In two years, manifestations
such as myalgia, arthralgia, asthenia, malaise, irritability,
memory  loss, headache, retro-orbital pain may be observed.67
Some DENV-infected patients also presented with psychiatric
symptoms such as thanatophobia and bug phobia.68 Estimat-
ing the incidence of psychiatric disturbance is difﬁcult because
of the lack of adequate literature to base the estimation.68–70
Alphavirus
Background
Alphavirus, a genus of the family Togaviridae, is found in all
continents, except Antarctica.71 This diverse genus includes
31 recognized species that can infect birds, rodents, amphib-
ians, reptiles, and human and nonhuman primates.72
The structural unit is a small, icosahedral capsid measuring
65–70 nm in diameter, surrounded by a lipid envelop of cellular
origin. The genome is composed of a positive single-stranded
11.5-kb-long RNA molecule, with a 7-methylguanosine cap at
the 5′-end and a polyadenylated tail at the 3′-end.73 It has two
open reading frames (ORFs), separated by an intergenic region.
The ﬁrst ORF encodes four non-structural proteins (nsP1-4),
necessary for the replication of viral RNA. An internal subge-
nomic promoter that lies immediately upstream controls this
ORF. The second ORF is translated into a single polyprotein
precursor, which is subsequently processed to form the cap-
sid protein (C), two envelope surface glycoproteins (E1 and E2),
and two small peptides (E3 and 6k). The organization of the
genome can be summarized as 5′-m7G-nsP1-nsP2-nsP3-nsP4-
(junction)-C-E3-E2-6K-E1-An-3′.72,74
The genus has three main clades: the Semliki Forest virus
clade, the equine encephalitis virus/Sindbis clade, and the
aquatic virus clade.71 The most studied viruses of this genus
are Sindbis and CHIKV. Thus, majority of the current knowl-
edge about molecular biology is based on studies with these
viruses.75
The clinically relevant alphaviruses can be roughly clas-
siﬁed into two groups, on the basis of a combination of
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hylogenetics, geographical distribution, and the clinical dis-
ase caused by them.
The viruses of the encephalitic group or New World
lphaviruses cause a ﬂu-like syndrome and have the potential
o progress to neurological conditions.76 These viruses occur
n the Americas and are associated with severe and lethal
ncephalitis. This group includes the Venezuelan Equine
ncephalitis (VEE), Eastern Equine Encephalitis (EEE), Western
quine encephalitis (WEE), and Madariaga antigenic complex
iruses.76
The viruses of the arthritogenic group or Old World
lphaviruses have a broader distribution; they were initially
dentiﬁed in the Old World (Europe, Asia, and Africa). They
ause malaise, rash, and sometimes incapacitating and long-
asting articular disease/myalgia.
They comprises the Ross River virus (RRV), CHIKV, Sindbis
irus (SINV), MAYV,  O’nyong-nyong virus (ONNV), and Barmah
orest virus (BFV).77
hikungunya
HIKV is the etiological agent causing Chikungunya fever (CF).
he virus was ﬁrst isolated in 1952 during an outbreak in
anzania78; however, it probably occurred centuries ago in
frica. It has been implicated in explosive outbreaks in all
ontinents.79
There is a serotype of CHIKV, which confers life-long immu-
ity to recovered individuals. However, four genotypes have
een described: the enzootic West African (WAf), the most
idespread East/Central/South African (ECSA) genotype, the
pidemic Asian genotype; and the WAf-derived Indian Ocean
ineage (IOL), responsible for epidemics in India, Indian Ocean
slands, and Europe since 2004.80
CHIKV ﬁrst appeared in the Americas in late 2013, in the
aribbean. In Brazil, some cases were reported since June
014. In September 2014, the Asian genotype reported in the
aribbean was detected in Amapá state, and the ECSA, which
as never detected in the Americas, was conﬁrmed in Bahia
tate. Since the ﬁrst detection, more  than 25,000 suspected
ases of CHIKV infection have been registered in Brazil.81,82
CF was ﬁrst described in Tanzania in 1955, when 115
atients were hospitalized because of acute onset of high
ever, severe joint pain, and rash.83 The term “Chikungunya”
omes from the Makonde language, meaning “that which
ends up”, in reference to the posture acquired by the patient
ecause of arthralgia. Arthralgia is the most important char-
cteristic of this illness, which also includes fever, headache,
ausea, and vomiting.84
linical  manifestations
F is an acute febrile illness that can occur in anyone at any
ge, and is usually self-limiting and rarely life-threatening.85
HIKV infection seems to induce long-lasting protective
mmunity, and epidemic peaks drop as an increasing per-
entage of the population improves their immunity.86 After
–7 (range, 2–12) days of incubation, the primary clinical
eatures of CHIKV infection include sudden onset of fever,
hills, headache, myalgia, maculopapular rash, and arthral-
ia, usually with a symmetric pattern, and especially in i o l o g y 4 7 S (2 0 1 6) 38–50 41
the wrist, knee, ankle, and small joints, which can often
end up being debilitating.87,88 The virus can be detected
in the joint tissues for up to 90 days, leading to local
inﬂammation.89 Up to 60% of the patients can suffer recur-
rent episodes of debilitating chronic arthritis years after the
infection is cleared.90,91 The chronic disease produced by
CHIKV is likely induced by deregulated inﬂammation dur-
ing the acute phase of disease and/or convalescence.92 Not
all individuals infected with the virus develop symptoms.85
Serosurveys indicate that 3–25% individuals with antibod-
ies to CHIKV have asymptomatic infections.93,94 The clinical
presentation of CF is often similar to that of DF, except for
the hemorrhagic or shock syndrome, which is rarely seen in
CHIKV infection,95 and the fact that febrile symptoms usually
resolve in 3–4 days, but prominent and prolonged arthral-
gia affect multiple joints, is more  common in CHIKV.96–98
Blood test abnormalities such as leukopenia, thrombocy-
topenia, hypocalcemia, and a mild-to-moderate increase in
liver function-determining values are seen during acute
infection.88,99 Other uncommon manifestations have also
been observed, such as nephritis,100 meningoencephalitis,101
encephalopathy,102 Guillain–Barré syndrome, acute ﬂaccid
paralysis, and palsies.103–105 However, neurologic, ophthal-
mologic, and hemorrhagic diseases associated with CHIKV
infection appear to be rare.106
High levels of CHIKV load typically last for 4–6 days and
can persist for up to 12 days after symptom onset.107,108 There
is no gold standard method in CHIKV diagnostics. Classical
virus detection methods such as virus isolation, detection of
viral antigens or nucleic acid, and detection of host antibodies
are commonly used.109
Treatment of CF is limited to supportive care: rest, ﬂu-
ids, antipyretics, and analgesics. Some studies suggest the
use of some drugs such as chloroquine, acyclovir, riba-
virin, interferon-, and corticosteroids for treating CHIKV
infection.88,110–112 Nonsteroidal anti-inﬂammatory drugs are
also used to treat the inﬂammation, but they can be used
only after ruling out DENV infection.109 Treatment with riba-
virin (200 mg  twice a day for seven days) has been effective in
relieving the pain in the lower limbs.113
The clinical and epidemiological similarities between
CHIKV infection and DF lead to misdiagnosis. CHIKV out-
breaks in endemic DENV areas often go unnoticed in areas
without diagnostic support.114,115 In fact, both CF and DF are
so similar that Halstead argued that the term “dengue” was
the ﬁrst descriptive for CF, but through the 19th century, the
term passed across the globe to eventually designate actual
DF.79
Mayaro
MAYV  is the etiologic agent causing Mayaro fever (MF), a
neglected disease of tropical Americas, where it is endemic.
The virus was ﬁrst isolated from a human in Trinidad in 1954,
and since then, clinical cases have been reported in many
countries in the tropical regions of South and Central America,
including Trinidad, Bolivia, Suriname, French Guiana, Guyana,
Peru, Venezuela, Colombia, Ecuador, Panama, and Brazil. Sero-
logical surveys also indicate the distribution in Costa Rica,
Guatemala, and Mexico.116
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Until now only two genotypes are known: the D genotype
restricted to the Pará state in Brazil, and the L genotype with
a wider distribution.116 As in case of CHIKV infection, MAYV
can go unnoticed.117
MAYV  is thought to be restricted to the sylvatic cycle,
mainly transmitted to non-human primates by canopy-
dwelling Haemagogus mosquitoes. Clinical infections are
accidental.118 However, these viruses have great potential
to emerge as a global pathogen, because urban mosquitoes
such as Ae. aegypti can be competent vectors for MAYV
transmission,119 like the path followed by CHIKV in the West-
ern Hemisphere.
As observed in case of CHIKV, MAYV  outbreaks can pass
unnoticed during DENV outbreaks. It is estimated that around
1% of all DENV-like cases in the northern region of South
America is caused by MAYV.117,120
Clinical  manifestations
Similar to CHIKV, MAYV  is an arthritogenic arbovirus, respon-
sible for sporadic infections or small outbreaks in the Amazon
region, usually limited to rural areas near or inside forests
because of the presence of the vector.121,122 The incuba-
tion period ranges from 7 to 12 days, with a transient short
viremia period of 3–7 days.116 MF  is a non-fatal, typically
DENV-like, and self-limiting acute febrile illness, character-
ized by headache, epigastric pain, myalgia, incapacitating
arthralgia, rash, chills, nausea, photophobia and vertigo. The
bilateral joint pain is the most prominent symptom; it devel-
ops during the acute phase of the disease, and can be highly
incapacitating, affecting the wrists, ankles, and small joints
of hands and feet, often along with edema. In more  than
50% patients, it can persist for several months after the infec-
tion, and often recur.123 The joint pain may persist for several
months.124 No mortality is associated with MAYV  infec-
tion, but the illness can cause signiﬁcant morbidity among
rural population,125 including intense arthralgia, temporary
incapacitation to work, and hospitalization. Few cases are
described in some subpopulations, especially the immuno-
compromised group, and are showed to be imported cases.126
Hemorrhagic manifestations in MAYV  infections have been
described, although rare.127
Diagnosis of MAYV  is based on classical viral detection
methods.116 Although high rates of antibodies are found
in some rural communities residing in the Amazon basin
in Brazil,128 it is difﬁcult to isolate MAYV,  because of rel-
atively short duration of viremia.116 No effective vaccine
or antiviral agent exists for the arthritogenic alphaviruses,
and the treatment chieﬂy relies on supportive modalities
such as non-steroidal anti-inﬂammatory medications116 and
chloroquine.129 As no vaccine or speciﬁc treatment is avail-
able, vector control is the most effective approach to limit the
spread of arboviruses.
Zika  fever
BackgroundZIKV is a member of the Spondweni serocomplex from the
genus Flavivirus and the family Flaviviridae. It is the etiological b i o l o g y 4 7 S (2 0 1 6) 38–50
agent causing Zika fever (ZF). Although it belongs to a differ-
ent serocomplex group, it is similar to other ﬂaviviruses such
as Ilheus (ILHV), Rocio (ROCV), and Saint Louis Encephalitis
(SLEV), which have already been isolated in Brazil.130,131 ZIKV
has a positive-sense, single-stranded, 10,794-nucleotide-long
RNA genome. The genome contains 5′- and 3′-UTRs ﬂanking
a single open reading frame (ORF) that encodes a polypro-
tein. This polyprotein is further cleaved into three structural
proteins: the capsid (C), premembrane/membrane (prM), and
envelope (E), and seven non-structural proteins (NS1, NS2A,
NS2B, NS3, NS4A, 2K, NS4B, and NS5).132
ZIKV replication is similar to the mosquito-borne replica-
tion observed in ﬂaviviruses, starting in the dendritic cells at
the site of the bite, and then spreading to the lymph nodes
and bloodstream. In general, the replicative process occurs
in the cytoplasm133; however, it is suggested that the pro-
teins of the ZIKV replicative complex may translocate to the
nucleus of infected cells,5 as occurs in case of the NS5 protein
of DENV-2, Yellow Fever (YFV), and Japanese Encephalitis (JEV)
viruses.133,134
At present, two known lineages are circulating in the world:
African (East and West) and Asian.135,136 In 2007, a major ZIKV
epidemic was detected in the Yap island in Micronesia, caused
by the Asian lineage,137,138 and from 2013, this lineage caused
epidemics in the Paciﬁc Islands (French Polynesia, New Cale-
donia, Cook Islands, Tahiti, and Easter Island).139–143 This same
lineage is responsible for the epidemics in Brazil,144–147 South
and Central Americas, as well as the imported cases in North
America and Europe.148–151
A phylogenetic study of the African and Asian lineages
showed that the African lineage is more  divergent than the
Asian lineage, with respect to the nucleotide and amino
acid sequences.137 The most widely known African isolate is
the MR766 (GenBank accession number: LC002520.1), which
shows 87–90% similarity with the isolates from French Poly-
nesia and Brazil.152,153 However, the infections caused by the
African lineage of ZIKV has never been related to congeni-
tal malformations or neurological alterations, as observed for
the Asian lineage in circulation, chieﬂy in Brazil.154 Thus, the
genetic relationship between the lineages is not well known
and needs to be studied.
What was known until now is that independent of the
origin, ZIKV lineages caused minor clinical consequences,
with cases of mild febrile illness. The clinical presentation
of ZIKV infection is usually not speciﬁc (mild fever, rash,
arthralgia, and conjunctivitis) and can be confused with
other diseases – most commonly DENV and CHIKV.155 The
most frequently reported symptoms include fever, conjunc-
tivitis, headache, myalgia, and pruritus.156 However, it is
very important to note that the clinical manifestations often
described as common ﬁndings in case of ZIKV infection, such
as conjunctivitis,156 may not be noted in some cases during
DENV outbreaks in endemic areas.157 Hematological ﬁndings
such as thrombocytopenia, a very common ﬁnding in DF,158
may also be associated with ZIKV infection, but with counts
generally around 100,000/mm3.159,160 Despite ZIKV infection
being typically associated with relatively mild illness, it is
also potentially associated with severe illness as well as with
neurological complications such as Guillain–Barré syndrome,
hearing difﬁculty,161 and microcephaly, at the moment. The
c r o b
a
m
c
B
b
m
t
o
B
w
m
t
b
s
t
h
M
s
a
h
a
c
2
A
o
Z
A
v
i
d
g
o
s
o
v
t
m
s
a
i
p
o
w
m
m
v
t
t
S
I
i
i
rb r a z i l i a n j o u r n a l o f m i 
ssociation between ZIKV infection during pregnancy and
icrocephaly was determined after the increase in micro-
ephaly cases in newborns in the northeastern region of
razil in 2015. This outbreak indicated a possible association
etween ZIKV infection during pregnancy and fetal malfor-
ations, which can be attributed to maternal-fetal virus
ransmission.162
This relationship began to be reviewed from the cases
f microcephaly and neurological abnormalities described in
razil. The virus was isolated from the amniotic ﬂuid of fetuses
ith microcephaly as well as from the blood of newborns with
icrocephaly, which suggested that the ZIKV is able to cross
he placental barrier.163–166 This assumption gained weightage
ased on the results from a study conducted in mice, which
howed neurological abnormalities in newborns infected with
he isolated Brazilian ZIKV.154
Transmission of ZIKV occurs through the bite of an infected
ematophagous mosquito (thus, a vector-borne disease).
any  known competent species are responsible for transmis-
ion of this virus: Ae.  africanus, Ae.  albopictus,  Ae.  aegypti, Ae.
picoargenteus, Ae.  luciocephalus, Ae.  vitattus, Ae.  furcifer,  and Ae.
ensilii.167–170 Brazilian cities are known to be infested by the
nthropophilic Ae.  aegypti, which is primarily responsible for
ausing epidemics in the country. However, only recently, in
016, the virus was isolated from a pool of naturally infected
e. aegypti,  present in the localities of Rio de Janeiro.171 Previ-
us studies have identiﬁed Ae.  aegypti naturally infected with
IKV in Malaysia170; however, this virus was also detected in
e. albopictus in Mexico,172 thus making it another potential
ector for the transmission of the virus into the country. Once
nfected, the virus incubation period in the vector may be ∼10
ays.173
Furthermore, entomological studies have recently sug-
ested that Culex, a tropical domestic mosquito widely
bserved in Brazil, might be able to transmit ZIKV since
ome arboviral infections are transmitted by several species
f Culex.174
The transmission of this virus occurs through the syl-
atic and urban cycles and it does not require the vector. In
he sylvatic environment, the cycle is maintained between
osquitoes and nonhuman primates, where rodents are also
uspected of acting as hosts.175 In the sylvatic cycle, humans
re accidental hosts. In 2015, ZIKV-positive primates were
dentiﬁed in the state of Ceará.176 This evidence supports the
ossibility that the primates act as reservoirs for ZIKV, as
bserved in case of YFV.172,176
The urban cycle occurs between mosquitoes and humans,
here the Ae.  aegypti,  Ae.  albopictus,  and Ae.  africanus
osquitoes act as the main vectors.152 Other forms of trans-
ission, quite a few of which are considered signiﬁcant, are
ertical166,177,178 and sexual transmission.179,180 Other routes
hat are still being studied include transmission via blood
ransfusion,181 breastfeeding,182 and infected host bite.183
ituation  in  Braziln early 2015, the Northeast region was faced with an increase
n the number of cases of an unidentiﬁed disease, character-
zed by mild fever, conjunctivitis, rash, and joint pain, which
emained for to 7 days. DF and Chikungunya, a viral fever that i o l o g y 4 7 S (2 0 1 6) 38–50 43
was ﬁrst recorded in the Americas in 2013, were suspected,
but not conﬁrmed.
In late April, a preliminary test conducted by the Insti-
tute of Health Sciences of the Bahia Federal University (UFBA)
identiﬁed the presence of ZIKV in biological samples col-
lected from patients. The disease, initially noted as a mild
illness, was treated as an international emergency a few
months later because of the ﬁrst evidence of its connec-
tion with the increase in microcephaly cases in the country
(Fig. 1).184
According to the WHO,  39 countries have reported the virus
in circulation since 2007. Of these, Brazil, French Polynesia,
El Salvador, Venezuela, Colombia, and Suriname have con-
currently published reports about the cases, the increase in
the incidence of Guillain-Barré syndrome and microcephaly
(particularly in Brazil).185
Gradually, ZIKV infections became a reality, with unimag-
inable consequences for an infection caused by arboviruses.
Although the occurrence of microcephaly and Guillain-Barré
syndrome is attributed to ZIKV, much remains to be investi-
gated. On February 1, 2016, the WHO  declared that the cluster
of microcephaly and ZIKV, mainly observed in the Brazilian
cases, as a “Public Health Emergency of International Concern”
(PHEIC)186; this is indicative of the extent of global emergency
(Fig. 1).
Clinical  manifestations
The current epidemic in Brazil attracted a lot of attention
because of the possible association of ZIKV with the unusual
increase in the occurrence of microcephaly in newborns. The
current ofﬁcial number (conﬁrmed until June 2016) of ZIKV
infection-related microcephaly cases is 1,638 cases of micro-
cephaly and other nervous system disorders, according to the
Brazilian Ministry of Health.187
Some neurological symptoms such as the Guillain–Barré
syndrome, characterized by weakness or paralysis caused by
autoimmunity to peripheral nerves, are frequent in other viral
infections too. The association with microcephaly is more
complex. Microcephaly is probably a direct teratogenic effect
of the virus, which affects the development of the central ner-
vous system. There are no studies proving microcephaly to be
the result of infection by other ﬂaviviruses, and most Brazil-
ian infants with microcephaly did not test positive for ZIKV.188
However, the real role of ZIKV infection in the development of
microcephaly remains unclear. Data obtained until date indi-
cate a supposed causal relationship between ZIKV infection
and microcephaly, which needs to be established with further
detailed studies.
It was recently proposed that the antibody-dependent
enhancement (ADE) phenomenon is related to ZIKV-linked
complications. This effect is well established for the aggra-
vation of infections caused by a second serotype of DENV. A
strong cross-reaction is suggested between DENV and ZIKV,
which is capable of stimulating the ADE effect in ZIKV-infected
patients that presents antibodies against DENV. It is noted
that the seroprevalence of DENV in South America popula-
tion exceeds 90%, and this may contribute to future studies
on pathogenesis and vaccine development against DENV and
ZIKV.189–191
44  b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 S (2 0 1 6) 38–50
Fig. 1 – Timeline of the ZIKV introduction in the South America.
s/20Adapted from http://www.bbc.com/portuguese/noticia
Researchers believe that the relationship between micro-
cephaly and ZIKV only emerged from the cases reported in
Brazil because the country is the largest in Latin America, with
a population larger and a density higher than those at previous
locations affected by ZIKV epidemic, which allows the highest
number of cases recorded.192
The Brazilian Ministry of Health is assessing changes in
the microcephaly assessment protocol, emphasizing that the
signs and symptoms of neurological disorders should be
included as the criteria for screening newborns, irrespective
of the presence of microcephaly; this, in turn, will expand the
investigation and improve the Brazilian surveillance system
for new cases of microcephaly.193,194
The fear instilled by ZIKV infections has led to a positive
change in the situation; several research centers in Brazil and
other countries came together to join forces in an attempt to
understand the biology of this virus and to develop tools for
the treatment of patients as well as for the prevention of the
infection.
In São Paulo, a group of 42 laboratories, called the Zika
network, and coordinated by the Institute of Biomedical Sci-
ences (ICB) at USP, are working together to better understand
the behavior of ZIKV, and thus improve the diagnostic meth-
ods and therapies and vaccine development. Regarding the
development of an effective vaccine against ZIKV, the Brazilian
government has partnered with the University of Texas Med-
ical Branch – UTMB (Galveston, Texas, USA), which is a world
center of arbovirus research, one of the most specialized cen-
ters in the development of vaccines, and a global reference as
a center of excellence in scientiﬁc research, in an attempt to
stop the consequences of infection by this arbovirus. Recently,16/02/160128 zika virus microcefalia trajetoria mdb.
a ZIKV vaccine was tested in mice, followed by efﬁciency anal-
ysis for protection against infection caused by the Brazilian
strain. In this study, the researchers used a single immu-
nization protocol with a DNA plasmid vaccine expressing the
full-length domain of ZIKV pre-membrane and envelope or
the puriﬁed inactivated virus vaccine; this provided complete
protection in susceptible mice against the Brazilian strain.195
Another researcher network, coordinated by FIOCRUZ-
Bahia, are involved in the development of an itinerant project
called ZIBRA (Zika in Brazil Real Time Analysis), which aims to
genetically map  ZIKV strains collected from several locations
in the Northeast regions (Natal (RN), João Pessoa (PB), Recife
(PE), Maceió (AL), Salvador, and Feira de Santana (BA)), between
2015 and 2016. Once the sequences are ready, the group will
be in a position to conduct epidemiological and evolutionary
analyses of the virus circulating in Brazil. These data will be
shared with all laboratories of the network as well as with the
Brazilian Ministry of Health.196
Another available tool to assess the relationship between
ZIKV and the host is ZIKV-CBD developed by FIOCRUZ-Minas,
which gathers information on disease-associated genes,
because the viral infection can interfere with gene expression
by altering cellular function.197
Despite the advances in technology, increase in informa-
tion sharing, and establishment of partnerships to better
understand the behavior of ZIKV, these tools appear to be “dis-
tant” of the population, for all the work remains restricted
to the laboratories. However, a quick test for the diagno-
sis of ZIKV, developed as a result of a collaborative project
between a Brazilian laboratory and a South Korean company,
has obtained the release certiﬁcate from ANVISA (National
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ealth Surveillance Agency). These kits will be distributed
hroughout the public healthcare system in Brazil once the
razilian Ministry of Health adopts this new modality.
inal  remarks
he biggest concern with arboviruses in Brazil remains the
eed for adequate diagnostics. Appropriate allocation of
esources, development of vaccines, and therapeutic manage-
ent depends on the correct assessment of the prevalence
f these viruses, which in turn, depends on the diagnostic
ethod used. However, the arboviruses discussed here share
any clinical features (e.g., fever, headache, myalgia, rash). In
razil, DENV is endemic, causing an overlap between this virus
nd other arboviruses. Other febrile illnesses such as measles,
yphoid, leptospirosis, and inﬂuenza can also present with
imilar characteristics, in particular, during the early phase,53
hereby leading to overlapping diagnosis. In many  regions of
razil, with low economic status and reduced availability of
iagnostic services, diagnosis usually depends exclusively on
he clinical manifestation.
These infections can be conﬁrmed by detecting the virus,
iral RNA, or antibodies. Historically, infections were diag-
osed based on serology, but with the advent of molecular
echniques, viral RNA can be easily detected by reverse
ranscriptase-polymerase chain reaction (RT-PCR) in speci-
ens obtained during the acute phase of infection.
There are no approved vaccines for any of these dis-
ases, and thus, the control of these diseases relies solely on
ector control. Therefore, improved awareness about these
rboviruses among physicians, healthcare personnel, and
oncerned authorities, in addition to a well-informed popula-
ion, is indispensable to tackle, in part, the inadequacies faced
n the diagnostic sector.
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